Objective: The objective of this study was to determine if differences exist in pelvic symptom distress and impact on women randomized to pessary versus behavioral therapy for treatment of stress urinary incontinence (SUI).
S
tress urinary incontinence (SUI) affects 15% to 35% of women, 1 creating a substantial societal and personal burden impacting on health-related quality of life (HRQOL), productivity, health care utilization, and costs. It is a substantial social problem contributing to embarrassment, negative self-perception, 2 impaired emotional and psychological well-being, 2 and impaired sexual relationships. 3 Although it is helpful for studies to quantify improvements in objective measures of urinary leakage such as pad weights or voiding diaries before and after an intervention, these clinical outcomes do not fully capture patients' changes in HRQOL with treatment. Validated symptom and HRQOL measures are available to characterize the bother and impact on a woman's daily life from various pelvic floor disorders including urinary incontinence, colorectal symptoms, and pelvic organ prolapse.
In the Ambulatory Treatments for Leakage Associated With Stress Incontinence (ATLAS) trial, compared with the pessary arm, more women in the behavioral arm reported having no bothersome stress incontinence symptoms (49% vs 33%, P = 0.006) and treatment satisfaction (75% vs 63%, P = 0.02), at 3 months, respectively. 4 In this planned secondary analysis of the ATLAS trial, our objective was to determine whether use of pessary or behavioral therapy for treatment of SUI results in overall improvements in bother and HRQOL from global urinary, prolapse, and colorectal symptoms. Relative differences in symptom improvement between the 2 treatments may help in counseling patients on their options of nonsurgical SUI management.
METHODS
This is a planned secondary analysis of a multicenter, randomized trial (ATLAS) that assigned 446 women with symptoms of SUI to continence pessary, behavioral therapy (pelvic floor muscle training and continence strategies), or combination therapy. 4 The methods and primary outcome of the ATLAS trial have been published. 4, 5 Eligible women at least 18 years old with symptoms of pure or predominant SUI were enrolled. Inclusion criteria included at least 2 SUI episodes on 7-day bladder diary and more SUI episodes than other types of incontinence episodes recorded on the diary. Women with continuous urinary leakage, current incontinence drug therapy, stages III or IV pelvic organ prolapse, incomplete bladder emptying, or neurological disorders associated with incontinence were excluded. Institutional review board approval was obtained at each of the 7 clinical sites and the data-coordinating center, and all participants provided written informed consent. Participants were randomly assigned to 1 of 3 treatment arms: pessary, behavioral therapy, or a combination of the 2 treatments. Randomization was stratified by incontinence type (SUI vs mixed) and severity (G14 vs Q14 incontinence episodes) determined by a 7-day bladder diary. Behavioral therapy was implemented in 4 visits at approximately 2-week intervals, and participants were given individualized prescriptions for daily pelvic floor muscle exercise and practice. Pessary treatment included a physician or nurse fitting the participant with a continence ring or dish. Outcomes were measured at baseline and 3, 6, and 12 months after randomization, with primary outcomes assessed at 3 months. All research personnel who collected patient-oriented outcome data were blinded to treatment group assignment.
Urinary incontinence and other pelvic symptoms and condition-specific HRQOL were assessed with validated questionnaires, including the Pelvic Floor Distress Inventory (PFDI), Pelvic Floor Impact Questionnaire (PFIQ), and Questionnaire for Urinary Incontinence Diagnosis (QUID). 6Y8 The PFDI includes a urinary scale (Urinary Distress Inventory [UDI]; score range, 0Y300) including 3 subscales (stress, irritative, and obstructive; each with score range 0Y100), as well as prolapse The QUID includes Stress and Urge scales (each with a score range of 0Y15), assessing the frequency of stress and urgency urinary incontinence symptoms. Higher QUID scores reflect increasing symptom frequency. Baseline characteristics and measures were compared between the pessary, behavioral treatment, and combined (pessary plus behavior) treatment groups using W 2 or 2-sample t tests. Changes from baseline to 3 months in the PFDI, PFIQ, and QUID scores were calculated (change score = 3 month score j baseline score). Paired t tests were conducted to compare the within-treatment changes at 3 months after randomization from baseline, and 1-way analyses of variance (ANOVAs) were conducted to compare the 3-month changes between the pessary, behavioral, and combined groups, adjusting for the baseline measures. We also report 12-month changes and comparisons between the pessary and behavioral groups.
RESULTS
Between May 2005 and October 2007, 741 women were assessed for eligibility, and 446 participants were randomly assigned to pessary (n = 149), behavioral therapy (n = 146), or combination therapy (n = 151). The 295 participants randomized to pessary or behavioral therapy had a mean age of 49 (SD, 11.9) years and a median vaginal parity of 2 (range, 1Y3). Eighty-five percent of the participants were white, and 10% were African American. Participants in the pessary, behavioral, and combined groups had similar baseline demographic characteristics and urinary incontinence and other pelvic floor symptom frequency, bother, and quality-of-life impact (Table 1) . Ninety-five percent of subjects completed the symptom and HRQOL measures at baseline, and 71% at 3 months. As previously reported, dropout patterns differed among treatment groups, with the pessary group having the highest attrition rate; however, intent-to-treat analyses and per-protocol analyses (using only subjects adherent to treatment assignment) did not significantly differ. 5 All groups (pessary, behavioral, and combined treatment) had a significant within-group improvement on each of the symptom and HRQOL measures at 3 months (Table 2) ; however, score improvement did not significantly differ between groups. Table 2 shows mean score improvement on each of the measures in all groups. Similarly, when the pessary and behavioral groups were compared at 1 year, there was no difference in symptom and quality-of-life scores among groups (Table 3) .
DISCUSSION
Pelvic floor symptom frequency, bother, and impact (HRQOL) improve similarly 3 months after pessary, behavioral, and combined pessary and behavioral therapy in women undergoing nonsurgical treatment for SUI. Barber et al 9 recently described the minimum important differences (MIDs) or minimal change that is considered to have a clinically significant impact for the UDI, UDI stress subscale, and UIQ of 11, 8, and 16 points, respectively. The improvements seen at both 3 months and 1 year in women in the ATLAS study receiving pessary and behavioral therapy were in excess of these estimates, suggesting that both forms of treatment result in clinically significant improvements in urinary incontinence. The MID for the QUID, also assessing urinary incontinence symptoms, has not been determined, although the changes seen in QUID scores in this trial exceeded 0.5-SD change, proposed as a conservative measure of clinical difference in patient-reported questionnaires. 7, 10 The MID for the POPDI has been estimated to be 37 points, whereas those for the colorectal subscales (CRADI, CRAIQ) have not been determined. 11 It is unlikely that the changes in the prolapse or colorectal scales represent clinically important differences using either existing estimates or a 0.5-SD change. These findings are not unexpected, as treatments were aimed at urinary incontinence symptoms and because eligibility criteria for the ATLAS trial included bothersome stress predominant urinary incontinence rather than prolapse or bowel symptoms; in fact, patients were excluded for greater than stage II prolapse. However, it is important to note that both the pessary and behavioral therapy groups experienced improvement, rather than deterioration, in bowel and prolapse symptoms. These findings of improvements in urinary, prolapse, and bowel symptoms have important implications for the counseling of women considering nonsurgical treatment for stress incontinence.
The improvements in the UDI and UIQ are less than those experienced after surgical management 11, 12 ; however, the improvements do represent clinically important reductions without the attendant morbidity of a surgical intervention. Although both women receiving pessary and behavioral therapy demonstrated clinically meaningful improvements in symptom frequency, bother, and HRQOL, there were no differences in those scores between the groups. Women in the behavioral therapy group experienced greater overall satisfaction with their therapy, and a smaller proportion had bothersome stress incontinence as assessed by the PFDI (33% vs 49%, P = 0.006) at 3 months. 4 However, when changes in the mean bother or HRQOL scores are compared, these between-group differences were not found. These data suggest that both behavioral and pessary treatment have a clinically important role in the treatment of stress incontinence. Women can be reassured of symptom improvement with either treatment modality, and individual patient characteristics and preferences can determine which nonsurgical therapy to use. The present study was not designed to evaluate which patient factors or preferences inform patient satisfaction or improvement with conservative treatment with either pessary or behavioral therapy. Women's perception of their goals for treatment and the attainment of these goals are related to their compliance with pessary management and likely impact their satisfaction with behavioral management as well. Given the lifestyle and treatment differences associated with pessary and behavioral therapy, it is likely that patients will self select between these forms of treatment. Based on the challenges in recruiting patients to a randomized trial comparing medical versus surgical management for mixed incontinence, 13 it is unlikely that these therapies can directly be compared with surgical management. Therefore, data on symptom and quality-of-life improvement becomes of paramount importance in the discussion of nonsurgical management with patients. Further investigation is warranted to determine which specific clinical and other patient factors may be associated with successful conservative management with either pessary or behavioral therapy.
